BioCatalystWatch
LEXXWorkspace / LEXX / OverviewCompany library

Lexaria Bioscience Corp.

Lexaria Bioscience Corp. (LEXX)

Price
Market cap
Next catalystFinal GLP-1-H26-7 group expected to complete dosing in mid-November 2026dehydratech-semaglutide · Dosing completionCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Other pipelines

DehydraTECH-CBD

DehydraTECH-semaglutide

PreINDP1P2P3FilingApproved
DehydraTECH-tirzepatide

PreINDP1P2P3FilingApproved

History / paused

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Operating
Investing
Financing

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

LEXX PR & News

PR & News

LEXX SEC archive